Published

An Evaluation of Therapeutic Harm Reduction and Psilocybin-Assisted Therapy Within Oregon's Measure 109

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: PDXScholar (Portland State University)
Date: 2025-10-02
Source: OpenAlex
DOI: Unavailable
PubMed: Unavailable

Authors

Bodhi Norton

Watch author

Derived topics and classifications

psilocybin Observational Study Toxicity Observational Study

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10 Announcement of special issue: ‘Behavioural pharmacology of ketamine and psychedelic drugs’Behavioural Pharmacology · 2026-05-06 Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USAAJPM Focus · 2026-05-01 Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurementPsychedelics · 2026-12-01 Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARASAIMSARA Journal · 2026-06-15 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02 Caution in interpreting value-related change after psilocybin: Comment on Kerr-Gaffney et al. (2026)Journal of Psychopharmacology · 2026-07-07